Further providing for schedules of controlled substances and providing for tianeptine-related adverse health events.
SB 946 would amend Pennsylvania’s Controlled Substance, Drug, Device and Cosmetic Act to place tianeptine into Schedule II of the state’s controlled substances schedules. By doing so, the bill would treat tianeptine as a tightly regulated controlled substance under Pennsylvania law, alongside other Schedule II drugs, and would make its legal status more restrictive for manufacture, sale, possession, and related enforcement purposes.
The bill also creates a new section directing the Department of Health to monitor and track adverse health events associated with tianeptine. The department would be authorized to collect information from health care providers, hospitals, poison control centers, coroners, medical examiners, and law enforcement; issue public advisories when the drug poses a significant public safety threat; and adopt regulations for reporting, data collection, and coordination with other agencies. The bill defines “adverse health event” broadly to include neurological, respiratory, cardiovascular, psychological, gastrointestinal, withdrawal-related, and life-threatening effects, as well as hospitalizations and deaths linked to suspected or confirmed tianeptine exposure.
If enacted, SB 946 would amend the state’s controlled substances schedule to add tianeptine to Schedule II, changing how the substance is regulated and enforced in Pennsylvania. It would also create a new public-health reporting and monitoring framework within the Department of Health, expanding state authority to gather data, coordinate with other agencies, and warn the public about tianeptine-related harms. The bill would affect health care providers, hospitals, poison control centers, coroners, medical examiners, law enforcement, and any individuals or businesses dealing with tianeptine.
Based on the bill text and the absence of recorded committee debate or votes in the provided materials, the apparent sentiment is precautionary and public-safety oriented. The measure is framed as a response to health risks associated with tianeptine, suggesting support for stronger regulation and surveillance rather than a contested policy expansion. No formal vote history or transcript comments are available to show opposition or amendment concerns.
No committee transcript or voting record was provided, so specific points of contention are not documented in the available materials. Potential areas of debate, based on the bill’s structure, would likely include whether tianeptine should be placed in Schedule II versus a different schedule, whether the Department of Health should have mandatory reporting and broad data-collection authority, and how the bill might affect legitimate medical or consumer uses of tianeptine. Any concerns would likely come from stakeholders affected by tighter controlled-substance regulation and reporting requirements.